Lucken Gherca connects makers whose launch date rests on one qualified facility with the validation and quality people who can stand up a second line before the date slips.

Public enforcement and filing data, updated as it publishes. This is the market I watch.

• 4 September 2026 Tampa sterile plant cited for an ineffective quality system. FDA told the firm to bring in a qualified consultant.
• 16 September 2026 A $600M revenue guidance cut traced to the ramp of a single contract manufacturing site, while demand stayed strong.
• 12 August 2026 California maker kept releasing sterile product after three failed media fills, with no defined quality unit responsibilities.
• August 2026 Three biologics licensed inside two weeks. Each one now needs commercial supply on a clock.

Sourced from FDA warning letters, CBER licence approvals, and SEC filings. Last pulled 1 October 2026.

No deal to point at yet — so here’s exactly what I put in motion.

• Cited site → quality and validation hire When a warning letter lands, FDA frequently instructs the firm to bring in qualified outside expertise. I put someone who has already run that remediation in the room while the response clock is still running.
• Operator → the sites that just found out If CAPA, aseptic risk, environmental monitoring or tech transfer is what you do, I bring you the plants that learned they need you this month rather than next quarter.

Building in the open. I’m working alongside myoProcess — a vetted B2B partner trusted across $1B+ in transactions — while I route my first introductions in this lane. My first closed match replaces this paragraph.

What I see in this market that outsiders miss.

• The hiring order inside a warning letter→
• Demand was never the constraint→